Valitor Inc. has presented preclinical results on VLTR-559, its long-acting anti-VEGF biologic candidate for durable wet age-related macular degeneration (AMD). VLTR-559, developed using Valitor’s ...

The Senate Appropriations Committee met July 31 to markup legislation that would fund the Department of Health and Human Services – including an additional $400 million for the National Institutes of ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...